Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy targets tough lung cancer

NCT ID NCT07531095

First seen Apr 24, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This study tests a combination of two drugs, tarlatamab and ZL-1310, with or without a third drug (durvalumab) in people with small cell lung cancer that has come back after standard treatment. The main goal is to find safe doses and check for side effects. About 160 adults will take part. Researchers will also watch for tumor shrinkage and how long any benefit lasts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baptist Cancer Center

    RECRUITING

    Memphis, Tennessee, 38120, United States

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Izmir Ekonomi Universitesi Medical Point Hastanesi

    RECRUITING

    Izmir, 35575, Turkey (Türkiye)

  • New York University Cancer Institute

    RECRUITING

    New York, New York, 10016, United States

  • Next Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.